Exicure (NASDAQ:XCUR) Trading Down 8.7%

Exicure, Inc. (NASDAQ:XCUR)’s share price traded down 8.7% during mid-day trading on Wednesday . The company traded as low as $0.58 and last traded at $0.58. 30,265 shares traded hands during trading, a decline of 93% from the average session volume of 412,076 shares. The stock had previously closed at $0.64.

Exicure Trading Down 3.1 %

The firm has a market capitalization of $4.85 million, a P/E ratio of 0.34 and a beta of 1.31. The stock has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.61.

Insider Transactions at Exicure

In other news, major shareholder Co. Ltd. Dgp sold 3,400,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $1.32, for a total transaction of $4,488,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Exicure

A number of hedge funds have recently made changes to their positions in XCUR. UBS Group AG raised its stake in shares of Exicure by 1,766.7% in the first quarter. UBS Group AG now owns 186,674 shares of the company’s stock worth $37,000 after purchasing an additional 176,674 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Exicure by 329.2% in the first quarter. Goldman Sachs Group Inc. now owns 147,703 shares of the company’s stock worth $29,000 after purchasing an additional 113,293 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Exicure in the second quarter worth about $66,000. 42.82% of the stock is currently owned by hedge funds and other institutional investors.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.